Holen Sie sich die Stockscreener-App
43.06
2.89%
-1.28
Handel nachbörslich:
42.83
-0.23
-0.53%
Grail Inc Aktie (GRAL) Neueste Nachrichten
Assessing GRAIL (GRAL) Valuation After Recent Share Price Volatility and Narrative Fair Value Gap - simplywall.st
Grail Inc. Announces CEO Transition - Contract Pharma
Grail CEO to retire after failed cancer detection trial - The Business Journals
GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges - Markets Mojo
(GRAL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Freidin, Grail CFO, sells $154k in GRAL stock - Investing.com Nigeria
Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor - TipRanks
GRAIL, Inc. 2025 Annual Report: Multi-Cancer Early Detection with Galleri, Company Strategy, and Key Business Risks - Minichart
GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026 - marketscreener.com
GRAIL names Josh Ofman as CEO, Bob Ragusa to retire June 1 - Investing.com
Cancer detection company GRAIL elevates Josh Ofman to lead multi-cancer efforts - Stock Titan
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity - AOL.com
Grail Inc’s Earnings Call Balances Momentum and Risk - TipRanks
A Persistent Patient’s Story - RealClearHealth
Aaron Freidin Sells 2,492 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 7,461 Shares of Stock - MarketBeat
Freidin, Grail CFO, sells $154k in GRAL stock By Investing.com - Investing.com Australia
Ofman Joshua J. (GRAIL) sells $177k in shares - Investing.com South Africa
Grail CEO Ragusa sells $409k in shares - Investing.com
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - ChartMill
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - Samsung Global Newsroom
GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ - The Cancer Letter
GRAIL, Inc. $GRAL Shares Purchased by JPMorgan Chase & Co. - MarketBeat
How Investors Are Reacting To GRAIL (GRAL) Mixed NHS-Galleri Trial Results And Ongoing Net Losses - Sahm
POM Health Announces Agreement with GRAIL to Offer Its Galleri® MCED Test - PR.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Vanguard Group Inc. Trims Stock Position in GRAIL, Inc. $GRAL - MarketBeat
Crcm LP Has $108.96 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc. Hits Day Low of $41.50 Amid Price Pressure - Markets Mojo
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - Seeking Alpha
Grail Insider Sold Shares Worth $1,881,417, According to a Recent SEC Filing - marketscreener.com
GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 9,573 Shares - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 37,504 Shares of Stock - MarketBeat
GRAL | GRAIL, Inc. Common Stock FinancialsIncome Statement - Quiver Quantitative
GRAIL (GRAL) president gets RSU grant, sells shares for taxes - Stock Titan
GRAIL (GRAL) CFO awarded 60,118 RSUs, sells shares to cover taxes - Stock Titan
GRAIL (GRAL) CEO sells 37,504 shares in automatic tax sell-to-cover - Stock Titan
GRAIL, Inc. (GRAL) Stock Analysis: Investor Outlook On A 67.21% Potential Upside - DirectorsTalk Interviews
GRAL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GRAIL, Inc. Hits Day Low of $52.56 Amid Price Pressure - Markets Mojo
GRAL: NHS-Galleri trial showed strong stage 4 cancer reduction and broad commercial momentum - TradingView
GRAIL (GRAL) Valuation Check As NHS Galleri Trial Data And Earnings Reset Growth Expectations - simplywall.st
GRAL: Affiliate to sell 36,923 vested RSU shares (Form 144) - Stock Titan
GRAL (NASDAQ) insider sale: Robert Ragusa sells 40,000 shares; 74,873 RSUs vested - Stock Titan
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
GRAIL (NASDAQ:GRAL) Shares Gap DownHere's Why - MarketBeat
Are Multi-Cancer Blood Tests Ready for Prime Time? - WSJ
(GRAL) Risk Channels and Responsive Allocation - Stock Traders Daily
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
Kaplan Fox Alerts Investors of Grail, Inc. (GRAL) to an Investigation of Potential Securities Law Violations - NewMediaWire
GRAIL stock dips in premarket after a sharp bounce as Galleri trial fallout hangs over GRAL - TechStock²
Primecap Management Co. CA Sells 33,346 Shares of GRAIL, Inc. $GRAL - MarketBeat
Here’s What Analysts Are Saying About Grail Inc. (GRAL) - Insider Monkey
After Grail’s Study Flop, What’s Left for Cancer Blood Screens - Barron's
Grail, Inc. (NASDAQ: GRAL) Shareholder InvestigationKaplan Fox Reviewing Potential Claims - The Globe and Mail
Why did my doctor push Grail’s dubious cancer test? - Endpoints News
0.34%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):